About Gamma Medica
Gamma Medica is dedicated to the development of advanced digital imaging technologies that address the growing importance of overcoming the critical shortcomings of mammography and other screening modalities in the early detection of breast cancer. The company's LumaGEM Digital MBI system is the first commercially available, dual head, fully solid-state digital imaging system utilizing cadmium zinc telluride (CZT) technology for molecular breast imaging. LumaGEM MBI is currently in use at premier hospitals and breast centers throughout the U.S.
Missing: Gamma Medica's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Gamma Medica's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Gamma Medica
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Gamma Medica is included in 5 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Health Monitoring & Diagnostics
Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Gamma Medica Patents
Gamma Medica has filed 1 patent.
Medical imaging, Neuroimaging, Medical physics, Radiopharmaceuticals, 3d nuclear medical imaging
Medical imaging, Neuroimaging, Medical physics, Radiopharmaceuticals, 3d nuclear medical imaging
Latest Gamma Medica News
Jan 30, 2023
January 30, 2023 08:12 AM Eastern Standard Time The global breast imaging market size is anticipated to reach USD 9.0 billion by 2030, registering a CAGR of 8.6%. The market growth mainly owes to the increase in the number of women suffering from breast cancer. For instance, according to Robert Koch Institute, the annual incidence of breast cancer in Germany was estimated to be approximately 72,000, with breast cancer being the most prevalent cancer in women. Moreover, as per a similar source, based on the incidence rate, one in eight women is expected to suffer from breast cancer once in a lifetime. Thus, impelling the market over the forecast period. Furthermore, the rising initiatives by various governments and NGOs to raise awareness about early diagnosis of breast cancer are anticipated to increase the demand for breast imaging. For instance, Pink Initiative, form Breast Cancer India is an online initiative program in which the program covers important topics such as early detection of breast cancer, and familial breast cancer, through their YouTube channel. Similarly, a joint initiative between Australian & state territory governments, 'BreastScreen Australia' is aimed at reducing deaths & illness from breast cancer by early detecting cancer. In this program, women aged 40 and above can have a free mammogram every 2 years. This is expected to increase awareness, and increase the demand for breast imaging, thereby, propelling the market growth. Major manufacturers are introducing new products and increasing the number of approved products, which is further expected to impel the demand in the coming years. For instance, in March 2018, The MAMMOMAT Revelation platform, from Siemens Healthineers, for enhanced mammography has been approved by the U.S. FDA. To target afflicted areas with only one click, this platform combines a new InSpect specimen imaging tool and new HD Breast Biopsy technology. In addition, the use of artificial intelligence (AI) in breast imaging has reduced the time required while maintaining image quality. Such product developments are expected to propel market growth. Breast Imaging Market Report Highlights The ionizing segment dominated the technology segment in 2022 owing to the introduction of new ionizing technology-based breast imaging technologies. Hospitals dominated the end-use segment in 2022 due to the presence of advanced and well-equipped breast imaging facilities. In 2022, North America dominated the breast imaging market with a market share of 37.87% 2022. This can be accredited to the rising number of breast cancer cases in this region. Asia Pacific is projected to impel at the fastest growth rate of CAGR 9.5% during the forecast duration. Increased prevalence of breast cancer, high R&D investments in breast cancer therapies, and developments in breast imaging modalities are the primary drivers driving the growth of the market. Market Dynamics
Gamma Medica Frequently Asked Questions (FAQ)
Where is Gamma Medica's headquarters?
Gamma Medica's headquarters is located at 12 Manor Parkway, Salem.
What is Gamma Medica's latest funding round?
Gamma Medica's latest funding round is Acquired.
How much did Gamma Medica raise?
Gamma Medica raised a total of $27.5M.
Who are the investors of Gamma Medica?
Investors of Gamma Medica include CMR Naviscan, Psilos Group, Hercules Capital and BDC Venture Capital.
Who are Gamma Medica's competitors?
Competitors of Gamma Medica include NeoChord, InPhenix, Seno Medical Instruments, Mirabilis Medical, nContact Surgical and 11 more.
Compare Gamma Medica to Competitors
Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.
National P.E.T. Scan is a provider of diagnostic imaging services with four freestanding outpatient positron emission tomography/computerized tomography ("PET-CT") facilities in Florida.
Gamma Medica Ideas, Inc. engages in designing, building, selling, and servicing pre-clinical and clinical imaging systems.
ULTRASPECT specializes in the development, production and sale of products dedicated to the enhancement of imaging quality and productivity performance of NM Gamma Cameras. Based on its , reconstruction algorithms technology, Wide-Beam Reconstruction (WBRTM), the company's imaging solutions shorten acquisition times and increase image resolution.
Halo Healthcare, formerly NeoMatrix, develops devices that allow women and doctors to promote optimal breast health. The company's premier product, the HALO Breast Pap Test, is a fully automated, non-invasive breast cancer risk assessment device designed for use in the primary care setting as part of an annual well-woman visit. The HALO Breast Pap Test is FDA approved for the collection of nipple aspirate fluid for cytological evaluation. The collected fluid can be used in the determination and/or differentiation of normal versus pre-malignant versus malignant cells.
QuantomiX develops products for rapid, high resolution imaging of wet samples.The company was founded in 2001 to commercialize its technology which, for a time, aims to enable direct imaging of fully hydrated samples in an electron microscope.With the Quantomix QXTM capsule product line, wet samples, including cells and tissues, can now be examined without any of the conventional treatments such as drying, deep freezing and sectioning. This opens the way to a better understanding of biomedical processes, to improved patient care, and to more effective pharmaceutical research.The QXTM capsules, that fit any Scanning Electron Microscope (SEM), close the resolution gap between conventional electron microscopy and light microscopy. They offer the convenient sample preparation of light microscopy.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.